Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therapy. Medical management is often associated with the development of treatment resistance leading ...
The most effective treatment for small-cell lung cancer is chemotherapy (using medications to kill cancer cells), either alone or in combination with radiation therapy (using high-dose X-rays or other high-energy rays to kill cancer cells). What Medications Treat Small-Cell Lung Cancer? Chemothe...
Evolutionary trajectories of small cell lung cancer under therapy ArticleOpen access13 March 2024 Main Lung cancer is the leading cause of cancer-related death worldwide, and represents 18% of cancer-related mortality and 11% of cancer incidence1. Yet, the biological mechanisms that underlie this ...
P-342 Diagnostic success rate of single day outpatient evaluation of suspected lung cancerdoi:10.1016/S0169-5002(05)80836-0van der Heijden, H.van der Link, M.Dekhuijzen, P.Elsevier Ireland LtdLung Cancer
of target cells for additional oncogenic events leading to acquisition of CICs. Alterations in the Hh pathway have been reported in a variety of cancers including medulloblastoma, glioma, stomach, colon, pancreatic cancer, basal cell carcinoma, rhabdomyosarcoma, breast, prostate, and lung cancer [31...
Recent nanotechnological aspects and molecular targeting strategies for lung cancer therapy 1Introduction The global burden of cancer is rising insidiously. With disquietingly high mortality rates (1 in 5 cancer deaths worldwide), lung cancer has been entitled as one of the most lethal forms of can...
With that cost structure, the additional expense of implementing lung cancer screening—if the rate of uptake of this service by the public is similar to the participation rate with colon cancer screening—will be about $700 million for the first year of national implementation of LDCT screening ...
lung cancer, accounting for approximately 85% of all patients [2]. Generally, surgical resection is considered the standard procedure for early-stage NSCLC, while chemotherapy is widely applied in advanced NSCLC patients. In particular, molecular targeted therapy regimens are routinely recommended to ...
Research on biomarker-driven therapy and immune check-point blockade in non-small cell lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also dramatically improved in an unprecedented speed. The personalized treatment p
Plausible explanations for lack of additional efficacy can be attributed to insufficient inhibition of tryptophan catabolism or due to disparity in expression of IDO and TDO amongst different cancer types [20]. Additionally, other tryptophan catabolites in the kynurenine pathway, such as 3-...